Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep884 | Growth hormone IGF axis - basic | ECE2017

Safety of growth hormone replacement therapy (GHRT) in adult patients with GH deficiency: data from kims

Camacho-Hubner Cecilia , Jonsson Peter , Aydin Ferah , Rajicic Natasa , Cara Jose , Abs Roger , Hey-Hadavi Judith

Background: The efficacy of recombinant human growth hormone replacement therapy (GHRT) has been demonstrated, in part, through clinical trials conducted worldwide. KIMS (Pfizer International Metabolic Database), established in 1994 and active until 2012, includes treatment outcome data and real world safety from 15 809 patients from 31 countries.Objective: The main objective of this analysis was to evaluate the long-term safety of patients with hypopitu...

ea0041ep700 | Growth hormone IGF axis - basic | ECE2016

Quality of Life (QoL) and IGF-I Status in Adults with Severe GHD

Shalet Stephen , Jonsson Peter , Pleil Andreas , Camacho-Hubner Cecilia , Abs Roger

Introduction: In adult patients with pituitary disease no relationship has been established between the biochemical severity of GHD and the degree of QoL impairment. Reasons may include heterogeneity of underlying pathologies, and the type of therapies received by GHD patients.Methods: The KIMS (Pfizer International Metabolic Database) database was used to focus solely on patients with non-functioning pituitary adenomas and prolactinomas treated by surge...

ea0049ep1010 | Pituitary - Clinical | ECE2017

Hypertension, acromegaly and pegvisomant treatment: Experience from ACROSTUDY

Vila Greisa , Jan vanderLely Arrt , Neggers Sebastian , Luger Anton , Webb Susan , Biller Beverly , Jonsson Peter , Hey-Hadavi Judith

Introduction: Hypertension (HTN) is a major cardiovascular (CV) risk factor and independent predictor of the increased mortality in patients with acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure (BP) levels, however little is known on the effect of pegvisomant (PEGV) treatment on HTN.Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional study monitoring the long-term safety of P...

ea0037ep805 | Pituitary: clinical | ECE2015

Pituitary apoplexy in GH-deficient adults treated with GH – a KIMS database retrospective study

Radian Serban , Jonsson Peter J , Camacho-Hubner Cecilia , Biller Beverly M K , Buchfelder Michael , AEkerblad Ann-Charlotte , Korbonits Marta

Background: Pituitary apoplexy (PitApo) has significant associated-morbidity and its management is not yet standardised.Aim: To describe prevalence and characteristics of PitApo patients in GH deficient (GHD) patients compared with two control populations.Patients and methods: Patients with ‘infarction-apoplexy’ GHD aetiology code were identified from Pfizer International Metabolic Database (KIMS). Baseline characteristic...

ea0022p619 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Lymphocytic hypophysitis: clinical characteristics and endocrine features of 64 GH deficient patients in KIMS: Pfizer International Metabolic Database

Bensing Sophie , Jonsson Peter , Hulting Anna-Lena , Cook David , Gordon Murray , Faust Michael , Koltowska-Haggstrom Maria , Casanueva Felipe

Objective: To characterize patients with GH deficiency associated with lymphocytic hypophysitis (LyH).Method: Patients with a diagnosis of LyH were identified in the KIMS database. The responsible clinicians were asked to confirm the diagnosis and to provide more detailed information on the patient by filling in a questionnaire.Results: One hundred and fifty patients with a diagnosis of LyH were identified in the database and 100 c...

ea0020p547 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Effects of 3 years growth hormone (GH) replacement in adult-onset growth hormone deficiency (GHD) due to controlled Cushing's disease (CD)

Hoybye Charlotte , Jonsson Peter J , Feldt-Rasmussen Ulla , Ragnarsson Oskar , Trainer Peter , Biller Beverly , Koltowska-Haggstrom Maria

Objective: Our study evaluates the contribution of untreated GHD to the phenotype in controlled CD, by comparing patients with GHD due to CD (n=322) and those with non-functioning pituitary adenoma (NFPA n=748) before and after 3 years of GH treatment.Methods: The patient cohorts were obtained from KIMS (Pfizer International Metabolic Database) and matched for age and gender. Duration between pituitary disease onset and GH start was 9.7 (CD...

ea0049gp192 | Pituitary &amp; endocrine Tumours | ECE2017

Long-term treatment with pegvisomant (Somavert®): Observations from 2090 acromegaly patients followed in ACROSTUDY

vanderLely Aart Jan , Biller Beverly , Brue Thierry , Buchfelder Michael , Ghigo Ezio , Pan kaijie , Jonsson Peter , Lavenberg Joanne , Strasburger Christian J. , Webb Susan , Camacho-Hubner Cecilia , Hey-Hadavi Judith

Introduction: Pegvisomant (PEGV) is approved for the treatment of acromegaly since 2003. This is the second interim analysis of data from ACROSTUDY, with the majority of patients treated for at least five years (yrs).Methods/design: ACROSTUDY is an international, open-label, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of PEGV. Patients were enrolled in the study on an ongoing basis.<...